Our focus is expanding affordable access to NARCAN® (naloxone HCl) Nasal Spray - the leading
community use naloxone - and progressing our pipeline of opioid overdose and addiction treatments.


Adapting for the Patient

ADAPT Pharma® is a privately-held company committed to expanding affordable access to NARCAN® (naloxone HCI) Nasal Spray and to developing new treatment options in the field of opioid overdose and addiction. Our mission is to provide simple, reliable, and accessible therapeutic options, ensuring that patients, and those who care for them, have access to the right treatment at the right time.

On November 18, 2015, after Fast Track Designation and Priority Review, the US Food and Drug Administration (FDA) approved NARCAN® (naloxone HCl) Nasal Spray 4mg for commercial use in the United States. NARCAN® Nasal Spray became commercially available in early 2016.

Visit www.NarcanNasalSpray.com to learn more. Find the official press release, including Indications and Important Safety Information here.

Group purchasers, such as law enforcement, firefighters, first responders, departments of health, educational facilities and community-based organizations can learn more about pre-ordering and purchasing NARCAN® Nasal Spray at (844) 4-NARCAN (844-462-7226) or customerservice@adaptpharma.com

In the United States, Adapt Pharma is located in Radnor, PA. Its global headquarters are in Dublin, Ireland.